Ma et al. present a pan-cancer analysis of 61 cancers that defines a TP53-based tripartite classification: TP53_top, TP53_plus, and Non_TP53. Analysis of 80,524 mutations and network integration reveals mutational heterogeneity, dysregulated transcription factor regulatory networks, and signaling pathway networks, providing a framework for precision oncology.